This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Core Business Units Aid McKesson's (MCK) Q2 Earnings?
by Zacks Equity Research
McKesson (MCK) is expected to gain from strong segmental performances in Q2 of fiscal 2019.
LabCorp (LH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
LabCorp (LH) might sustain its winning streak in third-quarter 2018 after having retained the same for the past few quarters. However, reimbursement pressure remains a concern.
Can Overall Growth Drive Thermo Fisher (TMO) Q3 Earnings?
by Zacks Equity Research
Thermo Fisher's (TMO) steadily strong analytical instrument business flaunts higher global demand.
Will Boston Scientific's (BSX) Q3 Earnings Reflect Overall Gain?
by Zacks Equity Research
We are optimistic about the IC business that will help Boston Scientific (BSX) maintain impressive global growth, owing to an innovative portfolio and robust commercial teams.
Can Abbott's (ABT) Steady Overall Growth Aid Q3 Earnings?
by Zacks Equity Research
Abbott (ABT) is consistently well-placed on a healthy growth trajectory within its Diabetes Care business for the past few quarters.
Here's Why You Should Invest in GNC Holdings (GNC) Right Now
by Zacks Equity Research
GNC Holdings (GNC) registers strong performance in e-commerce business and International segment. In fact, the company is putting an all-out effort to strengthen its international presence.
What's in Store for Cerner (CERN) This Earnings Season?
by Zacks Equity Research
Cerner's (CERN) third-quarter 2018 results are likely to be hurt by soft segmental results; guidance promising.
Will Instruments Drive Intuitive Surgical (ISRG) Q3 Earnings?
by Zacks Equity Research
Strong prospects in the Instruments and Accessories segment to drive Intuitive Surgical???s (ISRG) top line in the third quarter of 2018.
Amedisys to Buy Compassionate Care Hospice, Share Price Down
by Zacks Equity Research
Amedisys (AMED) adopts initiatives to boost hospice business. It expects to become the third-largest hospice provider in America with the latest buyout.
Varian Medical (VAR) Q4 Earnings: Is a Surprise in Store?
by Zacks Equity Research
Solid prospects in the Oncology segment to boost Varian Medical's (VAR) top-line performance in the fourth quarter of fiscal 2018.
What's in Store for Express Scripts' (ESRX) Q3 Earnings?
by Zacks Equity Research
Express Scripts (ESRX) likely to see soft PBM revenues in the third quarter of 2018; guidance strong.
Quest Diagnostics Boosts Health & Wellness, Acquires Provant
by Zacks Equity Research
Quest Diagnostics' (DGX) Provant Health acquisition is in line with its 'accelerate growth' strategy.
Can Masimo (MASI) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
QIAGEN Introduces New RNA-seq Library Preparation Solutions
by Zacks Equity Research
QIAGEN (QGEN) adopts initiatives to boost the NGS portfolio.
Wright Medical (WMGI) Takes Over Cartiva for $435M in Cash
by Zacks Equity Research
The Cartiva buyout will boost Wright Medical's (WMGI) Lower Extremities business.
Walgreens (WBA) Q4 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Walgreens' (WBA) Retail Pharmacy USA division witnesses comparable prescription growth and benefits from a strong retail prescription market.
Baxter & ASPEN Launch PN Tools to Boost Clinical Nutrition
by Zacks Equity Research
Baxter (BAX) and ASPEN's SmartPN lends the company a competitive edge in the MedTech space.
BioScrip Grows on CORE Plan, Reimbursement Issues Persist
by Zacks Equity Research
BioScrip (BIOS) progresses well on the back of its new multi-faceted CORE plan to improve its financial position.
Genomic Health's Test Gets Favored by New NCCN Guidelines
by Zacks Equity Research
Genomic Health (GHDX) forges ahead with the development of Oncotype DX Breast Recurrence Score test.
Express Scripts Introduces Medicare PDP Offerings for 2019
by Zacks Equity Research
Express Scripts' (ESRX) Medicare PDP to initiate coverage from Jan 1, 2019. The plan includes Walmart along with CVS Pharmacy and the Kroger Family of Pharmacies.
Accuray's (ARAY) Radixact System Used First Time in Germany
by Zacks Equity Research
Accuray's (ARAY) flagship radiotherapy systems have lucrative prospects.
Here's Why You Should Buy HealthEquity (HQY) Stock Right Now
by Zacks Equity Research
Strong presence in the HSA space and a solid guidance for fiscal 2019 make HealthEquity (HQY) a promising investment pick.
Here's Why You Should Invest in Boston Scientific Stock Now
by Zacks Equity Research
Boston Scientific (BSX) is coming up with better-than-expected earnings and revenue performances on the back of growth across all business lines and geographies.
Edwards Begins US CENTERA Study, Reintroduces Valve in Europe
by Zacks Equity Research
Edwards (EW) is recommencing commercial introduction of CENTERA valve in Europe after making certain minor modification to CENTERA's delivery system.
Here's Why You Should Hold Ecolab Stock in Your Portfolio
by Zacks Equity Research
Despite fluctuations in the cost of raw materials, Ecolab (ECL) to gain from strong performance in the Global Industrial segment.